Medspa and Dermatology Biologics Distributor in San Francisco

Vendor qualification for medspas and aesthetic practices

Medspas operating under physician supervision generally have an added qualification step compared with a physician-owned clinic: the supervising or medical director typically reviews vendor documentation before the practice adopts a new product line. We provide the certificate of analysis, donor eligibility summary, and lot release record so that review can happen before the first order, not after.

Dermatology and plastic surgery practices in San Francisco that already source other biologic or injectable products tend to fold this documentation into an existing vendor file rather than building a new process from scratch.

NPI-verified accounts and medical director sign-off

Every account requires an NPI number, and ordering is restricted to licensed physicians or to medspas ordering under the supervision of a licensed physician. Where a medspa has a named medical director, we recommend that the account be tied to that director's NPI so the chain of supervision is documented alongside the purchase history.

Verified accounts can schedule a peer-to-peer call to go through documentation, lot numbering, and record-keeping. These calls are limited to product and paperwork questions; they are not a substitute for a practice's own clinical or regulatory review.

Cold-chain shipping to a San Francisco location

Cryopreserved Wharton's jelly and exosome formats are shipped overnight on dry ice in validated containers and must move into -80 degree Celsius storage on arrival. Practices that stock multiple vial formats across more than one room or location should plan intake so that each lot is checked in and stored before use rather than left at the front desk. Lyophilized products ship shelf-stable and are handled differently on receipt.

Lot-level identifiers let a practice trace any single unit back to its source lot, which is useful if a medical director or compliance reviewer later asks which lot was used for a given visit.

Confirming claims and classification with counsel

We do not make disease, condition, or outcome claims about any product, and we recommend San Francisco practices hold their own marketing and intake materials to the same standard. Exosome products have no FDA approval and are generally regulated as biologic drugs; Wharton's jelly products are offered under the supplier's HCT/P framework, but whether a specific intended use qualifies under the minimal-manipulation and homologous-use criteria is a determination for the practice and its counsel.

We recommend verifying your practice's supervision structure and marketing claims with the California medical board and your own healthcare attorney, particularly given FDA warning letters issued in 2026 to distributors over website and social media claims in this category.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.